Expanding the clinicopathological spectrum of succinate dehydrogenase-deficient renal cell carcinoma with a focus on variant morphologies: a study of 62 new tumors in 59 patients.


Journal

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
ISSN: 1530-0285
Titre abrégé: Mod Pathol
Pays: United States
ID NLM: 8806605

Informations de publication

Date de publication:
06 2022
Historique:
received: 09 10 2021
accepted: 06 12 2021
revised: 03 12 2021
pubmed: 25 12 2021
medline: 10 6 2022
entrez: 24 12 2021
Statut: ppublish

Résumé

Most succinate dehydrogenase (SDH)-deficient renal cell carcinomas (RCCs) demonstrate stereotypical morphology characterized by bland eosinophilic cells with frequent intracytoplasmic inclusions. However, variant morphologic features have been increasingly recognized. We therefore sought to investigate the incidence and characteristics of SDH-deficient RCC with variant morphologies. We studied a multi-institutional cohort of 62 new SDH-deficient RCCs from 59 patients. The median age at presentation was 39 years (range 19-80), with a slight male predominance (M:F = 1.6:1). A relevant family history was reported in 9 patients (15%). Multifocal or bilateral tumors were identified radiologically in 5 patients (8%). Typical morphology was present at least focally in 59 tumors (95%). Variant morphologies were seen in 13 (21%) and included high-grade nuclear features and various combinations of papillary, solid, and tubular architecture. Necrosis was present in 13 tumors, 7 of which showed variant morphology. All 62 tumors demonstrated loss of SDHB expression by immunohistochemistry. None showed loss of SDHA expression. Germline SDH mutations were reported in all 18 patients for whom the results of testing were known. Among patients for whom follow-up data was available, metastatic disease was reported in 9 cases, 8 of whom had necrosis and/or variant morphology in their primary tumor. Three patients died of disease. In conclusion, variant morphologies and high-grade nuclear features occur in a subset of SDH-deficient RCCs and are associated with more aggressive behavior. We therefore recommend grading all SDH-deficient RCCs and emphasize the need for a low threshold for performing SDHB immunohistochemistry in any difficult to classify renal tumor, particularly if occurring at a younger age.

Identifiants

pubmed: 34949766
doi: 10.1038/s41379-021-00998-1
pii: S0893-3952(22)00058-8
doi:

Substances chimiques

Succinate Dehydrogenase EC 1.3.99.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

836-849

Informations de copyright

© 2021. Crown.

Références

Gill, A. J. Succinate dehydrogenase (SDH) deficient neoplasia. Histopathology 72, 106–116 (2018).
doi: 10.1111/his.13277 pubmed: 29239034
Gill, A. J. Succinate dehydrogenase (SDH) and mitochondrial driven neoplasia. Pathology 44, 285–292 (2012).
doi: 10.1097/PAT.0b013e3283539932 pubmed: 22544211
Gill, A. J. et al. Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC and SDHD in paraganglioma-phaeochromocytoma syndromes. Hum. Pathol. 41, 805–814 (2010).
doi: 10.1016/j.humpath.2009.12.005 pubmed: 20236688
Gill, A. J. et al. Succinate dehydrogenase deficiency is rare in pituitary adenomas. Am. J. Surg. Pathol. 38, 560–566 (2014).
doi: 10.1097/PAS.0000000000000149 pubmed: 24625421
Turchini, J. & Gill, A. J. Morphological clues to succinate dehydrogenase (SDH) deficiency in pheochromocytomas and paragangliomas. Am. J. Surg. Pathol. 44, 422–424 (2020).
doi: 10.1097/PAS.0000000000001415 pubmed: 31789631
Williamson, S. R. et al. Report from the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers: III: Molecular Pathology of Kidney Cancer. Am. J. Surg. Pathol. 44, e47–e65 (2020).
doi: 10.1097/PAS.0000000000001476 pubmed: 32251007
Gill, A. J. et al. Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients. Am. J. Surg. Pathol. 38, 1588–1602 (2014).
doi: 10.1097/PAS.0000000000000292 pubmed: 25025441
Gill, A. J. et al. Renal tumors associated with germline SDHB mutation show distinctive morphology. Am. J. Surg. Pathol. 35, 1578–1585 (2011).
doi: 10.1097/PAS.0b013e318227e7f4 pubmed: 21934479
Gill, A. J. et al. Renal tumors and hereditary pheochromocytoma-paraganglioma syndrome. N Engl. J. Med. 364, 885–886 (2011).
doi: 10.1056/NEJMc1012357 pubmed: 21366490
Gill, A. J. et al. Immunohistochemistry for SDHB divides gastrointestinal stromal tumors (GISTs) into 2 distinct types. Am. J. Surg. Pathol. 34, 636–644 (2010).
doi: 10.1097/PAS.0b013e3181d6150d pubmed: 20305538
Dwight, T. et al. Familial SDHA mutation associated with pituitary adenoma and pheochromocytoma/paraganglioma. J. Clin. Endocrinol. Metab. 98, E1103–E1108 (2013).
doi: 10.1210/jc.2013-1400 pubmed: 23633203
Williamson, S. R. et al. Succinate dehydrogenase-deficient renal cell carcinoma: detailed characterization of 11 tumors defining a unique subtype of renal cell carcinoma. Mod. Pathol. 28, 80–94 (2015).
doi: 10.1038/modpathol.2014.86 pubmed: 25034258
Trpkov, K. et al. Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) Update on Renal Neoplasia. Mod. Pathol. 34, 1167–1184 (2021).
doi: 10.1038/s41379-021-00737-6 pubmed: 33526874
Trpkov, K. et al. New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) Update on Renal Neoplasia. Mod. Pathol. 34, 1392–142 (2021).
doi: 10.1038/s41379-021-00779-w pubmed: 33664427
Gill, A. J. et al. Germline SDHC mutation presenting as recurrent SDH deficient GIST and renal carcinoma. Pathology 45, 689–691 (2013).
doi: 10.1097/PAT.0000000000000018 pubmed: 24150194
Smith, S. C. et al. A distinctive, low-grade oncocytic fumarate hydratase-deficient renal cell carcinoma, morphologically reminiscent of succinate dehydrogenase-deficient renal cell carcinoma. Histopathology 71, 42–52 (2017).
doi: 10.1111/his.13183 pubmed: 28165631
Korpershoek, E. et al. SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas. J. Clin. Endocrinol. Metab. 96, E1472–E1476 (2011).
doi: 10.1210/jc.2011-1043 pubmed: 21752896
Yakirevich, E. et al. A novel SDHA-deficient renal cell carcinoma revealed by comprehensive genomic profiling. Am. J. Surg. Pathol. 39, 858–863 (2015).
doi: 10.1097/PAS.0000000000000403 pubmed: 25724004
Ozluk, Y. et al. Renal carcinoma associated with a novel succinate dehydrogenase A mutation: a case report and review of literature of a rare subtype of renal carcinoma. Hum. Pathol. 46, 1951–1955 (2015).
doi: 10.1016/j.humpath.2015.07.027 pubmed: 26476567
Jiang, Q. et al. A novel germline mutation in SDHA identified in a rare case of gastrointestinal stromal tumor complicated with renal cell carcinoma. Int. J. Clin. Exp. Pathol. 8, 12188–12197 (2015).
pmcid: 4680348 pubmed: 26722403
McEvoy, C. R. et al. SDH-deficient renal cell carcinoma associated with biallelic mutation in succinate dehydrogenase A: comprehensive genetic profiling and its relation to therapy response. NPJ Precis. Oncol. 2, 9 (2018).
doi: 10.1038/s41698-018-0053-2 pubmed: 29872718
Moch, H., Humphrey, P. A., Ulbright, T. M. & Reuter, V. E. WHO Classification of Tumours of the Urinary System and Male Genital Organs 4th edn. (IARC Press, 2017).
Li, Y. et al. Re-evaluation of 33 ‘unclassified’ eosinophilic renal cell carcinomas in young patients. Histopathology 72, 588–600 (2018).
doi: 10.1111/his.13395 pubmed: 28898443
Ricketts, C. et al. Succinate dehydrogenase kidney cancer: an aggressive example of the warburg effect in cancer. J. Urol. 188, 2063–2071 (2012).
doi: 10.1016/j.juro.2012.08.030 pubmed: 23083876
Kennedy, J. M. et al. Clinical and morphologic review of 60 hereditary renal tumors from 30 hereditary renal cell carcinoma syndrome patients: lessons from a contemporary single institution series. Med. Oncol. 36, 74 (2019).
doi: 10.1007/s12032-019-1297-6 pubmed: 31332543
Casey, R. T. et al. Clinical and molecular features of renal and pheochromocytoma/paraganglioma tumor association syndrome (RAPTAS): case series and literature review. J. Clin. Endocrinol. Metab. 102, 4013–4022 (2017).
doi: 10.1210/jc.2017-00562 pubmed: 28973655
Dwight, T. et al. Loss of SDHA expression identifies SDHA mutations in succinate dehydrogenase-deficient gastrointestinal stromal tumors. Am. J. Surg. Pathol. 37, 226–233 (2013).
doi: 10.1097/PAS.0b013e3182671155 pubmed: 23060355
Samaratunga, H. et al. Granular necrosis: a distinctive form of cell death in malignant tumours. Pathology 52, 507–514 (2020).
doi: 10.1016/j.pathol.2020.06.002 pubmed: 32561208
Trpkov, K. et al. Low-grade oncocytic tumour of kidney (CD117-negative, cytokeratin 7-positive): a distinct entity? Histopathology 75, 174–184 (2019).
doi: 10.1111/his.13865 pubmed: 30895640
Al-Obaidy, K. I. et al. EWSR1-PATZ1 fusion renal cell carcinoma: a recurrent gene fusion characterizing thyroid-like follicular renal cell carcinoma. Mod. Pathol. 34, 1921–1934 (2021).
doi: 10.1038/s41379-021-00833-7 pubmed: 34099871
Kuroda, N. et al. ALK rearranged renal cell carcinoma (ALK-RCC): a multi-institutional study of twelve cases with identification of novel partner genes CLIP1, KIF5B and KIAA1217. Mod. Pathol. 33, 2564–2579 (2020).
doi: 10.1038/s41379-020-0578-0 pubmed: 32467651
Benn, D. E. et al. Bayesian approach to determining penetrance of pathogenic SDH variants. J. Med. Genet. 55, 729–734 (2018).
doi: 10.1136/jmedgenet-2018-105427 pubmed: 30201732

Auteurs

Talia L Fuchs (TL)

Sydney Medical School, The University of Sydney, Sydney, Australia.
Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, St Leonards, NSW, Australia.
NSW Health Pathology, Department of Anatomical Pathology, Royal North Shore Hospital, NSW Health Pathology, St Leonards, NSW, Australia.

Fiona Maclean (F)

Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, St Leonards, NSW, Australia.
Anatomical Pathology, Douglass Hanly Moir Pathology, Sonic Healthcare, Macquarie Park, NSW, Australia.
Discipline of Pathology, Macquarie Medical School, Macquarie University, Macquarie Park, NSW, Australia.

John Turchini (J)

Sydney Medical School, The University of Sydney, Sydney, Australia.
Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, St Leonards, NSW, Australia.
Anatomical Pathology, Douglass Hanly Moir Pathology, Sonic Healthcare, Macquarie Park, NSW, Australia.
Discipline of Pathology, Macquarie Medical School, Macquarie University, Macquarie Park, NSW, Australia.

A Cristina Vargas (AC)

Sydney Medical School, The University of Sydney, Sydney, Australia.
Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, St Leonards, NSW, Australia.
Anatomical Pathology, Douglass Hanly Moir Pathology, Sonic Healthcare, Macquarie Park, NSW, Australia.
Discipline of Pathology, Macquarie Medical School, Macquarie University, Macquarie Park, NSW, Australia.

Selina Bhattarai (S)

Leeds Teaching Hospital, Leeds, UK.

Abbas Agaimy (A)

Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.

Arndt Hartmann (A)

Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.

Chia-Sui Kao (CS)

Stanford University Medical Center, Stanford, CA, USA.

Carla Ellis (C)

Northwestern University, Chicago, IL, USA.

Michael Bonert (M)

McMaster University, Hamilton, Ontario, Canada.

Xavier Leroy (X)

Institut de Pathologie, Centre de Biologie-Pathologie, CHRU, Lille, France.

Lakshmi P Kunju (LP)

University of Michigan, Ann Arbor, MI, USA.

Lauren Schwartz (L)

University of Pennsylvania, Philadelphia, PA, USA.

Admire Matsika (A)

Mater Health, Brisbane, QLD, Australia.
University of Queensland, Brisbane, QLD, Australia.

Sean R Williamson (SR)

Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic Cleveland, Ohio, OH, USA.

Priya Rao (P)

The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Mukul Divatia (M)

Houston Methodist Hospital, Houston, TX, USA.

Rosa Guarch (R)

Complejo Hospitalario de Navarra, Navarra, Spain.

Ferran Algaba (F)

Fundació Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain.

Marcelo L Balancin (ML)

Oncocentro Foundation, Sao Paulo, Brazil.

Ming Zhou (M)

Tufts Medical Center, Boston, MA, USA.

Hemamali Samaratunga (H)

University of Queensland, Brisbane, QLD, Australia.
Aquesta Pathology, Toowong, QLD, Australia.

Isabela Werneck da Cunha (IW)

Institute of Pathology, Rede D'OR-São Luiz and D'Or Institute for Research and Education (IDOR), São Paulo, Brazil.

Fadi Brimo (F)

McGill University, Montreal, Canada.

Andrew Ryan (A)

TissuPath Pathology, Melbourne, VIC, Australia.

David Clouston (D)

TissuPath Pathology, Melbourne, VIC, Australia.

Manju Aron (M)

University of Southern California, Los Angeles, CA, USA.

Marie O'Donnell (M)

NHS Lothian, Edinburgh, Scotland, UK.

Emily Chan (E)

University of California San Francisco, San Francisco, CA, USA.

Michelle S Hirsch (MS)

Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Holger Moch (H)

Department of Pathology and Molecular Pathology, University Hospital Zurich and University Zurich, Zurich, Switzerland.

Chun-Yin Pang (CY)

St. Teresa's Hospital, Kowloon, Hong Kong, SAR, China.

Cheuk Wah (C)

Queen Elizabeth Hospital, Kowloon, Hong Kong, SAR, China.

Weihua Yin (W)

Peking University Shenzhen Hospital, Shenzhen, China.

Joanna Perry-Keene (J)

Aquesta Pathology, Toowong, QLD, Australia.
Sunshine Coast University Hospital, Pathology Queensland, Birtinya, QLD, Australia.

Asli Yilmaz (A)

Department of Pathology and Laboratory Medicine, University of Calgary and Alberta Precision Labs, Calgary, AB, Canada.

Angela Chou (A)

Sydney Medical School, The University of Sydney, Sydney, Australia.
Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, St Leonards, NSW, Australia.
NSW Health Pathology, Department of Anatomical Pathology, Royal North Shore Hospital, NSW Health Pathology, St Leonards, NSW, Australia.

Adele Clarkson (A)

Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, St Leonards, NSW, Australia.
NSW Health Pathology, Department of Anatomical Pathology, Royal North Shore Hospital, NSW Health Pathology, St Leonards, NSW, Australia.

Gerhard van der Westhuizen (G)

PathCare, Mediclinic Bloemfontein Hospital, Bloemfontein, South Africa.

Ella Morrison (E)

NHLS, Bloemfontein Area, Bloemfontein, South Africa.

Jonathan Zwi (J)

Lab Plus, Auckland DHB, Auckland, New Zealand.

Ondrej Hes (O)

Medical Faculty and University Hospital Plzen, Charles University, Prague, Plzen, Czech Republic.

Kiril Trpkov (K)

Department of Pathology and Laboratory Medicine, University of Calgary and Alberta Precision Labs, Calgary, AB, Canada.

Anthony J Gill (AJ)

Sydney Medical School, The University of Sydney, Sydney, Australia. a.gill@sydney.edu.au.
Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, St Leonards, NSW, Australia. a.gill@sydney.edu.au.
NSW Health Pathology, Department of Anatomical Pathology, Royal North Shore Hospital, NSW Health Pathology, St Leonards, NSW, Australia. a.gill@sydney.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH